Key Highlights

  • In open-label Part A of the SKYLINE Phase 2 ulcerative colitis trial, SPY001 achieved clinical remission in 40% of patients and endoscopic improvement in 51%.
  • SPY002 reached 33% clinical remission and SPY003 reached 20%, and all three antibodies met the primary endpoint of a lower Robarts Histopathology index score.
  • SPY072 missed primary endpoints in psoriatic arthritis and axial spondyloarthritis, so the company will not advance it in rheumatic diseases.
  • Randomized Part B induction data are due in the third quarter of 2027, and pivotal hidradenitis suppurativa studies for SPY072 are planned for 2027.

Part A Figures Laid Out in the Quarterly Filing

Spyre Therapeutics (NASDAQ:SYRE) lodged its Quarterly Report for the period ended September 30, 2026 on November 3, 2026. The company is a clinical-stage biotech developing extended half-life antibodies aimed at alpha4beta7, TL1A, IL-23 and IL-17A/F for immune-mediated diseases. In Part A of its SKYLINE Phase 2 ulcerative colitis trial, SPY001, SPY002 and SPY003 each met the primary endpoint, lowering the Robarts Histopathology Index by 9.2, 10.7 and 10.0 points. Clinical remission reached 40%, 33% and 20% respectively, and endoscopic improvement reached 51%, 42% and 30%. Induction data were cut off on July 27, 2026 and locked on August 27, 2026; the Week 12 shift in modified Mayo Score measured minus 3.7 for SPY001 and SPY002, and minus 3.5 for SPY003.

Open-Label Design, Combination Thesis and the Hidradenitis Bet

Part A was open-label and tested one dose of each single agent with no placebo arm, so its numbers should not be set directly against other companies' trials. Management argues that combining targets, for example SPY120 (alpha4beta7 plus TL1A), SPY130 (alpha4beta7 plus IL-23) and SPY230 (TL1A plus IL-23), might produce fuller control of disease. Part B is randomized and placebo-controlled, is enrolling ahead of schedule against a raised enrollment target, and will report induction data in the third quarter of 2027. In hidradenitis suppurativa, the SKYLIGHT trial started in September 2026 with topline results expected in late 2027 or early 2028.

A Rheumatic Setback and the Risks Still Ahead

The filing also documents a setback. In rheumatoid arthritis, SPY072 beat placebo on several endpoints in August 2026, but management said those results fell short of its internal bar for prioritizing that indication. The company said in November 2026 that the psoriatic arthritis and axial spondyloarthritis sub-studies fell short on primary endpoints; SPY072 nevertheless tolerated well, but rheumatic programs will not move forward. Cash, net loss and runway numbers were absent from the material reviewed, leaving the funding requirement for 2027 readouts unmeasured. Combination programs remain unproven in controlled trials, and a miss in Part B could reset expectations.

Where Things Stand

The 40% figure is encouraging but preliminary: it comes from an open-label, single-agent cohort rather than a randomized combination study. Spyre Therapeutics (NASDAQ:SYRE) demonstrated that each of the three antibodies hit its primary histology goal and looked safe relative to in-class peers, and it has dropped SPY072 from rheumatic indications. The decisive data are the placebo-controlled Part B results due in the third quarter of 2027 and the hidradenitis readout around late 2027 or early 2028. Until then, cash and trial execution are the main variables, and cash figures were absent from the extract. Investors should therefore treat these figures as early signals rather than settled evidence.